Mode
Text Size
Log in / Sign up
Phase 1 Completed N=26 Randomized Quadruple-blind Treatment

A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain

Radiculopathy Lumbar
Source: ClinicalTrials.gov NCT05298306 ↗
Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcomePrimary: The Number of Participants With Adverse Events by Dose (Part A) — 1; 1; 2; 2 participants

Summary

The study consists of two parts. Part A will evaluate the safety and tolerability of intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with placebo, in patients with lumbar radicular pain. Healthy volunteers are not accepted for Part B.

Outcome Measures

OutcomeResultp-value
PRIMARY
The Number of Participants With Adverse Events by Dose (Part A)
1; 1; 2; 2; 0; 0
PRIMARY
Change in Baseline Pain With Intravenous LAT8881 in Patients With Lumbar Radicular Pain (Part B)
3.7; 3.1; -0.8; -0.3; -0.8; -0.3 0.5196
SECONDARY
Maximum Plasma LAT8881 Concentration (Cmax) After Intravenous LAT8881 (Part A)
12.6; 10.2; 13.8
SECONDARY
Time to Maximum Plasma LAT8881 Concentration (Tmax) After Intravenous LAT8881 (Part A)
0.08; 0.08; 0.08
SECONDARY
Area Under the Concentration Time Curve From Zero to Infinity (AUC0-inf) After Intravenous LAT8881 (Part A)
NA; NA; NA
SECONDARY
Terminal Elimination Half Life (T1/2), (Part A)
NA; NA; NA
SECONDARY
Patient General Impression of Change (Part B)
2; 0; 3; 2; 4; 11
SECONDARY
The Number of Participants With Adverse Events After Intravenous LAT8881 in Patients With Lumbar Radicular Pain (Part B)
5; 4; 0; 0; 0; 0

Eligibility Criteria

Key Inclusion Criteria

For PART A, the following inclusion criteria apply:

  • Male or female healthy participants, aged 18-49 years inclusive at screening;
  • Body mass index of ≥ 19.0 kg/m2 to ≤ 32.0 kg/m2 at screening;
  • Female participants must not be pregnant or breastfeeding
  • Male participants with a female partner of childbearing potential must use highly effective contraception for 60 days after the last dose of study treatment

For PART B, the following key inclusion criteria apply:

  • Male or female participants with unilateral pain, aged 18 years and above at screening;
  • Body mass index of ≥ 19.0 kg/m2 at screening.
  • Female participants must not be pregnant or breastfeeding
  • Male participants with a female partner of childbearing potential must use highly effective contraception for 60 days after the last dose of study treatment
  • Presenting with a history of unilateral pain, radiating into a lower limb, of lancinating, burning, stabbing or electric quality, of duration of >3 months.
  • Pain scores (NRS) for average daily leg pain at rest at the relevant nerve root of a mean of ≥4/10 and ≤9/10 for 3 days prior to treatment, with a minimum of >3/10 on any day.
  • Demonstration of disc herniation within 6 months by CT or MRI at a segmental level consistent with the clinical features.
  • The site of disc herniation must affect L1-2, L2-3, L3-4, L4-5 or L5-S1.
  • The patient is willing to keep all analgesic medication and other therapy usage stable or decreased in the week prior to, and a week after, IP administration.
  • The patient is in good general health, with the exception of the presenting condition under study

Key Exclusion Criteria

The following key exclusion criteria apply for both PART A and PART B:

  • Any condition which might be a risk to participant safety or interfere with study evaluation
  • Unwillingness to abstain from alcohol or nicotine products as required

The following additional key exclusion criteria apply to PART B:

  • A history of significant pain unrelated to disc herniation that would significantly compromise assessment of leg radicular pain.
  • Radiological evidence of foraminal stenosis or of clinically significant spinal stenosis .
  • Lumbar back surgery related to the specific disc.
  • Injection of an epidural corticosteroid injection within 3 months of screening.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05298306). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search